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Abstract
In recognition of the growing influence of cell biology in retrovirus research, we recently organized
a Summer conference sponsored by the American Society for Cell Biology (ASCB) on the Cell
Biology of HIV-1 and other Retroviruses (July 20–23, 2006, Emory University, Atlanta, Georgia).
The meeting brought together a number of leading investigators interested in the interplay
between cell biology and retrovirology with an emphasis on presentation of new and unpublished
data. The conference was arranged from early to late events in the virus replication cycle, with
sessions on viral fusion, entry, and transmission; post-entry restrictions to retroviral infection;
nuclear import and integration; gene expression/regulation of retroviral Gag and genomic RNA;
and assembly/release. In this review, we will attempt to touch briefly on some of the highlights of
the conference, and will emphasize themes and trends that emerged at the meeting.
Meeting report: The conference began with a keynote address from W. Sundquist on the
biochemistry of HIV-1 budding. This presentation will be described in the section on Assembly and
Release of Retroviruses.
Viral fusion, entry, and transmission
Eric Freed opened the meeting by introducing work from
his laboratory that identified the cholesterol-binding
agent amphotericin B methyl ester (AME) as a potential
compound to block HIV-1 replication [1]. Addition of
AME to cultured cells inhibited HIV-1 replication in T cells
and this group demonstrated that AME induced a block at
the level of viral entry. However, extended viral kinetics
revealed a recovery of HIV-1 replication. This was shown
to be due to the emergence of AME-resistant mutants.
Sequencing data revealed changes in the cytoplasmic tail
of the transmembrane envelope glycoprotein, gp41. Trun-
cation of gp41 also reversed the AME-imposed block to
both HIV-1 and simian immunodeficiency virus (SIV)
infection. Surprisingly, Eric Freed's group revealed that
gp41 cleavage by the viral protease was responsible for the
AME resistance.
Walther Mothes then introduced his work in mostly spec-
tacular videomicroscopy clips and images on retrovirus
transmission from an infected to an uninfected cell. He
showed real-time video microscopy of murine leukemia
virus (MLV) particles traveling or "surfing" on cytonemes
that are long-lived actin-rich filopodial processes that
bridge these cells. He made important points that indi-
cated that because virus particles are free to move in any
direction, changes in receptor-envelope affinity dictated
the cumulative unidirectional flow of particles along
cytonemes towards the cell body of uninfected cells. Virus
movement along filopodia was shown to be dependent
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described [2]. Thus MLV and other retroviruses surf along
these processes to regions of the cell that are vulnerable to
viral entry, likely to regions where there is active cytoskel-
etal remodelling. These results reveal another example of
viruses hijacking host machineries to allow for efficient
spreading of the infection from cell to cell.
Another important mediator of viral entry was high-
lighted by Michel Tremblay whose work has historically
focused on integral membrane-spanning intracellular
adhesion molecules (ICAMs) that are incorporated within
the envelopes of retroviruses. Focusing on ICAM-1, a
known host factor that dramatically enhances infectivity
of virions [3], Michel Tremblay demonstrated that ICAM-
1 interacts with its receptor, LFA-1 in microdomains and
clusters at the cell surface of primary cells. This was shown
to favor the release of viral capsids into target cells rather
than endocytosis of virions. Similar to receptor-ligand
interactions, the lateral diffusion of LFA-1 and its subse-
quent clustering were shown to be necessary to confer
infectivity. Thus, the ICAM-1/LFA-1 ligand/receptor inter-
action facilitates infection, but is also important for the
generation of the virological synapse during cell-to-cell
transmission of retroviruses (described below) and thus
represents a critical early step in infection.
Boashan Zhang (R. Montelaro lab) identified the host
receptor for the ungulate equine infectious anemia virus
(EIAV), a lentivirus that infects cells of the monocyte-mac-
rophage lineage to cause progressive degenerative diseases
without clinical immunodeficiency. This was identified as
equine lentivirus receptor-1 (ELR1) that is related to the
family of TNF receptor (TNFR) proteins [4]. With the aim
of dissecting the molecular mechanisms of viral entry, this
group described studies in which it mapped the domain
of ELR1 that interacts with the EIAV Env to an amino-ter-
minal cysteine-rich domain. It is clear that this work will
provide a deeper understanding of some of the first virus-
host interactions required for entry of this retrovirus.
The transmission of HIV-1 from dendritic cells to CD4+ T
cells represents one of the crucial stages for the establish-
ment of infection [5]. Li Wu provided some insight into
host factors that influence cell-to-cell transmission from
dendritic cells to T cells. He presented some intriguing
findings on how host gene (CD4 and DC-SIGN) expres-
sion levels influence HIV-1 infection and subsequent
transmission from dendritic cells to T cells. This group
provided evidence that CD4 expression levels could dra-
matically impact on viral transmission. Co-expression of
CD4 strongly inhibited DC-SIGN-mediated HIV-1 trans-
mission to T cells, and this was also echoed in studies in
which Nef [6] was expressed in dendritic cells to downreg-
ulate CD4 levels. Furthermore, DC-SIGN expression levels
were conversely upregulated by Nef and this impacted
positively on HIV-1 transmission to T cells. Cumulatively,
the results indicate that dendritic cells not only mediate
HIV-1 trans-infection, but to facilitate cell-to-cell trans-
mission, they can also be productively infected in order to
express Nef at a later stage.
The final talk of this session was from Quentin Sattentau
who extended his work on deciphering the mechanisms
involved in the cell-to-cell transfer of HIV-1 between T
cells. His group was instrumental in demonstrating that
this occurs via the formation of a virological synapse that
allows for efficient infection of neighboring cells for HIV-
1 [7], a phenomenon that is also observed during HTLV-1
dissemination [8]. It has been appreciated for several
years that cell-to-cell transmission relies on critical events
that require a functional host cell cytoskeleton and clus-
tering (or polarization) of cell surface receptors such as
CD4 and cytoskeletal components. In this work, Sattentau
evaluated the contributions of the cellular trafficking
machinery (vesicles and cytoskeleton) and identified a
vesicular compartment that could contribute to cell-to-
cell transmission. The involvement of the microtubule-
based cytoskeleton was also shown to be involved not
only because the microtubule organizing center reposi-
tions proximally to the virological synapse, but also
because the depolymerization of microtubules leads to
the disruption of Gag and Env polarization at the synapse.
Gag and Env were found in a spontaneously-formed, tet-
raspanin-rich vesicular compartment containing CD63,
CD81 and CD9 at the plasma membrane in HIV-1-
infected primary T cells. Sattentau suggested that this
vesicular compartment shares some similarity to that
found in the T cell secretory apparatus and thus would be
enabling for HIV-1 transmission by targeting viral compo-
nents to the virological synapse and promoting viral trans-
mission and dissemination.
Post-entry restrictions to retroviral infection
The recent discovery that host proteins TRIM5α and
APOBEC3G are able to potently restrict retroviral infec-
tion, and that retroviruses have evolved mechanisms to
counter these restrictions [9,10], has led to a tremendous
increase in the number of studies aimed at understanding
the early post-entry phase of retroviral infection. The ses-
sion on post-entry restrictions began with a talk from Paul
Bieniasz in which he described experiments designed to
investigate whether diverse TRIM family members could
inhibit HIV-1 infection if artificially targeted to the incom-
ing capsid. Indeed, a number of TRIMs could disrupt HIV-
1 infectivity when fused to cyclophilin A, which binds
capsid. Gag chimeras in which the HIV-1 capsid domain
was replaced with that of SIV (which lacks the ability to
bind cyclophilin A) escaped this restriction. Some of these
findings were echoed in a talk and a recent paper [11]Page 2 of 10
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cating that fusing heterologous coiled-coil domains to
sequences that target capsid (e.g., cyclophilin A) can
restrict HIV-1 infection. In this case, specificity was dem-
onstrated by the ability of mutations in capsid that block
cyclophilin A binding to reverse the restriction. From
these studies emerged the concept that the presence of two
independent domains, one that provides coiled-coil or
multimerization function and the other that possesses
Gag targeting activity, is in some cases sufficient to gener-
ate a restriction factor. In his talk, P. Bieniasz described a
study that has taken advantage of our increased knowl-
edge of post-entry restriction factors to engineer HIV-1
variants that are able to bypass blocks imposed on HIV-1
infection by non-human primate cells. These HIV-1 vari-
ants display greatly enhanced ability to replicate in rhesus
macaque cells, making them potentially useful in devel-
oping non-human primate models for HIV-1 infection.
The mechanism of TRIM5α-mediated post-entry restric-
tion was explored in a presentation by Edward Campbell
from T. Hope's laboratory. While it has been demon-
strated that proteasome inhibitors are not able to relieve
the block to HIV-1 infection imposed by rhesus TRIM5α
[12], Campbell and coworkers nevertheless observed that
proteasome inhibition could rescue the defect in post-
entry synthesis of viral DNA but could not reverse the
block in the synthesis of 2-LTR circles. These results imply
that TRIM5α imposes a block at more than one step in the
post-entry pathway. Visualization of incoming virus
(using GFP-Vpr) in cells expressing rhesus TRIM5α and
treated with proteasome inhibitors revealed the accumu-
lation of viral particles in rhesus TRIM5α cytoplasmic
bodies. These observations suggest that TRIM5α may
sequester incoming viral cores and induce their proteas-
ome-mediated degradation [13].
Several presentations on post-entry restriction imposed by
APOBEC3G and related APOBEC proteins began with an
unexpected twist from Klaus Strebel's lab. H. Takeuchi
and coworkers observed that replication of SIVagm in
human T-cell lines requires Vif, but that no deamination
is evident in Vif's absence. Further investigation into this
phenomenon indicated that cyclophilin A is incorporated
into Vif-deficient SIVagm virions but is absent from WT
SIVagm virions [as reported previously [14,15]]. The rele-
vance of cyclophilin A incorporation in the Vif(-) replica-
tion defect was demonstrated by the finding that
replication of SIVagm in cyclophilin A knock-out cells or
in cells treated with cyclosporine A (which blocks cyclo-
philin A activity) is Vif-independent. These results reveal a
novel APOBEC-independent role for Vif in promoting SIV
infection.
Mariana Marin (D. Kabat's lab) presented work aimed at
identifying factors associated with APOBEC3G using mass
spectrometry analyses. Over 100 proteins, most with
mRNA-binding activity, were identified [16]. Their associ-
ation with APOBEC3G was mRNA-specific, as binding
was released by RNaseA treatment. The authors also
observed that APOBEC3G is part of a polysomal popula-
tion and could bind many diverse mRNAs, including viral
genomic RNA. These results suggested that APOBEC3G
complexes might be involved in regulating retroviral gene
expression patterns at the level of mRNA export, transla-
tion and stability.
Initial studies strongly suggested that the major mecha-
nism by which APOBEC3G blocks HIV-1 infectivity is
through deamination of the nascent viral DNA post-entry,
and consequent G-to-A hypermutation of the viral
genome. However, several lines of evidence have sug-
gested recently that APOBECs can restrict retroviruses and
other viruses (e.g., hepatitis B virus) through deamina-
tion-independent mechanisms [17]. Reubin Harris
addressed this controversial issue in his presentation. He
observed that APOBEC3B and APOBEC3F are able to
inhibit the retrotransposition of human long interspersed
element 1 (L1). Significantly, catalytically inactive
mutants of APOBEC3B are still able to inhibit L1 retro-
transposition [18]. In contrast, deamination activity of
human APOBEC3G was required for full levels of anti-
HIV activity in this study. Harris also investigated the
behavior of the APOBECs from artiodactyls (e.g., cattle,
sheep, and pigs) and found a human-APOBEC3F-like pro-
tein that displays anti-HIV-1 activity that was not counter-
acted by HIV-1 Vif. Again, catalytic activity was a major
part of the mechanism. Thus, depending on the retroid
target, DNA cytosine deamination may or may not be an
integral part of the restriction mechanism.
In the final talk of this session, Vineet KewalRamani pre-
sented work from his lab on a novel post-entry inhibitor
of lentiviral infection, a truncated SR-family protein. This
factor inhibits infectivity of primate lentiviruses (but not
that of MLV) early post-entry by disrupting the stability
and/or trafficking of the incoming viral genome. Analysis
of HIV-1/MLV chimeras identified CA as the viral determi-
nant of sensitivity to the antiviral factor. Indeed, the
KewalRamani lab was able to select for HIV-1 variants that
escaped this restriction and demonstrate that the changes
responsible for escape mapped to CA. This antiviral factor
thus provides an important new tool for understanding
early post-entry steps in the HIV-1 replication cycle.
Nuclear import and integration
The third session of the conference began with a presenta-
tion from Frederic Bushman focused on the targeting of
retroviral integration. Previous studies from this groupPage 3 of 10
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gration [19,20]; in contrast, MLV prefers to integrate at
transcription start sites [21] whereas avian sarcoma-leuko-
sis virus (ASLV) integration sites are nearly random
[19,22]. The integrase (IN) enzyme itself appears to be the
major viral determinant of target site selection [23], and
the host factor lens epithelium-derived growth factor/p75
(LEDGF/p75) is an important player in this process [24].
To gain more information about HIV-1 target site selec-
tion, Bushman's lab used the powerful "454" sequencing
method [25] to obtain 40,000 new sites of HIV-1 integra-
tion in infected Jurkat T cells. In addition to confirming
the preference of HIV-1 integration for transcriptionally
active regions, this study also showed that a collection of
histone post-translational modifications positively associ-
ated with transcription had a stimulatory effect on integra-
tion whereas DNA methylation had a negative effect.
Stuart Le Grice provided a progress report on his labora-
tory's efforts, in collaboration with NCI-Frederick's
Molecular Targets Discovery Program, NICHD in
Bethesda, and the University of Pittsburgh, to develop
selective inhibitors of HIV-1 ribonuclease H (RNase H). A
total of ~250,000 compounds have been screened in this
project, and several potent and specific inhibitors of HIV-
1 RNase H have been identified. One of these, β-thujapli-
cinol, has also been shown to synergize with a nonnucle-
oside RT inhibitor, indicating that both the DNA
polymerase and RNase H active sites can be simultane-
ously targeted. Structural studies aimed at defining the
binding sites for these inhibitors are underway.
Returning to the role of LEDGF/p75 in HIV-1 integration,
Eric Poeschla presented the results of his rather heroic
efforts to intensify the knock-down of LEDGF/p75 using
stable hairpin RNAs (shRNAs) expressed from lentiviral
vectors. Previous reports had indicated that LEDGF/p75
binds HIV-1 IN, promotes IN nuclear localization and
prevents its degradation by tethering the protein to chro-
matin (e.g., [26]). However, discordant results had been
obtained regarding the impact of LEDGF/p75 depletion
on HIV-1 infectivity. By intensifying the knock-down
strategy, Poeschla's lab was able to virtually eliminate
LEDGF/p75 expression, and, in particular, to strip detect-
able LEDGF/p75 from the DNase- and salt-releasable
chromatin fraction. As a consequence, HIV-1 infectivity
was reduced by ~30-fold. Feline immunodeficiency virus
(FIV) infectivity was also greatly reduced; in contrast,
MLV, whose IN protein does not bind LEDGF/p75, was
unaffected. Rescue of HIV-1 infectivity was restored by
adding back siRNA-resistant LEDGF/p75. Overexpression
of the IN-binding domain of LEDGF/p75 also potently
blocked HIV-1 infectivity [27]. The authors hypothesized
that the failure to observe major defects in HIV-1 infectiv-
ity in previous LEDGF/p75 siRNA experiments was due to
the presence of a small but functionally significant pool of
chromatin-bound LEDGF/p75 that resisted depletion.
Continuing with the LEDGF/p75 theme, Alan Engelman
reported their use of an alternative strategy to eliminate
LEDGF/p75 expression; namely, the creation of mouse
LEDGF/p75 knock-out cells. Infection of these cells with
HIV-1 vectors was markedly reduced, whereas MLV infec-
tivity was unaffected. Interestingly, preintegration com-
plexes (PICs) isolated from LEDGF/p75 knock-out cells
were defective for integration in vitro and this defect was
shown to be due to the lack of LEDGF/p75 in the PICs.
These findings suggest that LEDGF/p75 is an essential
component of the HIV-1 PIC.
Post-translational modifications of viral proteins are now
becoming important for their activities during virus repli-
cation in LTR transactivation, for instance. For HIV-1 IN,
this was also shown to be the case by Lara Manganaro (M.
Giacca lab) who demonstrated that p300, a cellular acetyl-
transferase that regulates chromatin conformation
through the acetylation of histones, also acetylates IN and
controls its activity [28]. Acetylation of C-terminal lysines
(Lys264, 266 and 273) and conserved (in retroviruses)
regions of IN were shown to be important for DNA asso-
ciation, IN strand transfer activity and possibly IN protein
stability in HIV-1 infected cells. Future work will focus on
temporal nature of acetylation and what other functions
of IN are affected by this post-translational modification.
Gene expression/regulation of retroviral gag and 
RNA
Kathy Boris-Lawrie opened this session and spoke about
virus-host interactions involving the activities of the post-
transcriptional control element (PCE). The PCE is a highly
structured RNA element in the 5'untranslated region of
RNA that was identified in some retroviruses including
avian spleen necrosis virus and Mason-Pfizer monkey
virus [29,30], reticuloendotheliosis virus strain A and
HTLV-1 (Bolinger and Boris-Lawrie, unpublished). Affin-
ity chromatography using the PCE as a bait followed by
mass spectrometry analyses identified the RNA helicase A
(RHA), DDX9 in the eluate, a protein with well-described
roles in transcription, and less well established roles in ret-
roviral splicing and nuclear export [31]. The specificity of
RHA interaction was shown by co-immunoprecipitation
of Flag-tagged RHA and PCE and lack of co-immunopre-
cipitation with a bank of nonfunctional PCE mutants. The
rescue of co-immunoprecipitation by compensatory
mutations that restore the stem-loop structure of the PCE
determined that RHA specifically recognized the double
stranded structure of PCE. Downmodulation of this RNA
helicase by siRNA together with polysome analysis
revealed that it is necessary for Gag expression whereby
downmodulation did not affect RNA splicing, export orPage 4 of 10
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the gag mRNA. By contrast, translation of global cellular
mRNA was unaffected [32]. This work revealed that RHA
might be a general factor that specifically associates with
selected structured RNAs of both viral and human origin
to facilitate their translation.
Karen Beemon described her group's recent efforts to
understand the regulation of Rous sarcoma virus (RSV)
post-transcriptional regulation that relies on peculiarities
of the RSV RNA sequences. Normally, an RNA undergoes
degradation via nonsense-mediated decay (NMD) when a
premature termination (or stop) codon (PTC) is encoun-
tered by ribosomes in an mRNA and this in many cases is
dependent on the deposition of a multi-protein complex
(the exon junction complex or EJC) on the RNA and splic-
ing events in the nucleus [33]. In earlier work from Bee-
mon's lab, RSV gag RNA was shown to be a substrate for
NMD when PTCs were introduced in gag RNA [34]. How-
ever, RSV genomic RNAs as well as other retroviral RNAs
are not only considered aberrant because of the lack of
splicing events, the presence of introns and the possible
absence of EJCs, but also appear to be canonical substrates
for NMD with their unusually long 3'UTRs (that for gag
RNA is >7 kb) [35]. The Beemon lab uncovered a 401-
nucleotide cis-acting sequence downstream of the gag ter-
mination codon that prevented recognition of the gag
mRNA, and more specifically, the bona fide termination
codon by the NMD machinery [36]. While it remains to
be determined whether similar regulatory sequences are
present in other retroviruses to prevent recognition of this
cellular RNA surveillance machinery, these results point to
yet another complex regulatory circuit to maintain levels
of retroviral RNAs and to ensure their utilization for struc-
tural protein synthesis.
A little further upstream in the gene expression phase of
HIV-1 replication are splicing regulation and 3'end
processing of RNA. These processes are highly complex for
retroviruses like HIV-1 due to the presence of multiple
positive and negative regulatory elements in the viral
genome and the activities of multiple host proteins in
controlling their activity [37]. Alan Cochrane demon-
strated that the modulation of host protein gene [Ser- and
Arg-rich (SR) splicing factors, hnRNPs] expression
impacted on splicing and 3'end-processing of HIV-1 RNAs
and modulated expression of HIV-1 structural proteins.
These studies again highlight the complex regulation that
occurs during the maturation of retroviral RNAs. The key
role of polyadenylation in expression of viral genes was
exploited by this group to develop a strategy to selectively
inhibit HIV-1 expression by targeting the binding of mod-
ified U1 snRNPs to regions of RNA adjacent to the polya-
denylation signal. The magnitude of the inhibition
observed coupled with the high degree of conservation of
the sequences targeted suggests that this approach might
have an application in targeting HIV-1 in a gene therapy
approach.
In the first of several talks focused on retroviral Gag target-
ing, Akira Ono presented work from his lab on the viral
and cellular determinants of HIV-1 Gag targeting to the
plasma membrane and multivesicular body (MVB).
Building on previous results that the phosphoinositide
phosphatidyl (4,5)bisphosphate [PI(4,5)P2] plays an
important role in Gag targeting [38], Ono examined the
binding of HIV-1 Gag to liposomes either containing or
lacking PI(4,5)P2. These studies indicated that the pres-
ence of PI(4,5)P2 enhanced binding of WT HIV-1 Gag but
not that of Gag mutants containing mutations in a basic
region of matrix (MA) implicated in Gag targeting. These
results are consistent with the recent structural demonstra-
tion of a direct interaction between HIV-1 Gag and
PI(4,5)P2 [39]. To investigate the viral determinants of
Gag targeting, Ono examined the localization of various
HIV-1 Gag mutants and chimeras, both in the presence or
absence of PI(4,5)P2 depletion. Intriguingly, localization
of Gag to the MVB (either upon PI(4,5)P2 depletion or
mutation of the MA basic domain) was prevented by
mutation or removal of the NC domain. These results
implicate NC in the targeting of Gag to the MVB, perhaps
by promoting its assembly-induced retention at the MVB.
While Gag is a powerful targeting protein that can alone
direct virus-like particle formation from cells, Gag also
encounters multiple host proteins and machineries dur-
ing its transit in the cell. Gag is also considered critical to
genomic RNA trafficking, selection and encapsidation.
Much attention has been paid to the multitude of host
proteins involved in transporting HIV-1 RNAs out of the
nucleus[40] since this process still represents a suitable
therapeutic target. Once the RNA gets into the cytoplasm
however, few details are known about the fate of retroviral
RNAs. While the genomic RNA must be both translated
and encapsidated, trafficking may rely in part on vesicular
[41,42] and another part on RNP trafficking mechanisms
[43]. Andrew Mouland showed work demonstrating the
involvement of hnRNP A2 in nucleocytoplasmic and
intracytoplasmic trafficking of the genomic RNA using
siRNA-mediated knockdown and in situ fluorescence
imaging techniques. This work identified the microtubule
organizing center as a site via which HIV-1 genomic RNA
enters the cytoplasm [44], a site that has been shown to be
targeted by incoming viral capsids before entry into the
nucleus for HIV-1 and other viruses [45]. This work high-
lighted the importance of host proteins and machineries
in the targeting of viral components during the gene
expression and assembly phases of the retroviral replica-
tion cycle.Page 5 of 10
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D. Murray's group, described studies aimed at measuring
the association of HIV-1 MA with liposomes of varying
composition. These studies had their genesis in similar
work from this group on RSV MA. The MA used in the
binding assays was either myristylated or not, and was
either monomeric or artificially dimerized. The results
emphasized the importance of negatively charged lipids
in MA binding to membrane. Furthermore, dimerization
greatly increased the affinity of HIV-1 MA for liposomes.
This and previous work from these authors emphasizes
the role of electrostatic interactions and Gag multimeriza-
tion in the binding of both HIV-1 and RSV Gag to mem-
brane.
In studies focused on defining the assembly pathway of
HIV-1 Gag, Delphine Muriaux used subcellular fractiona-
tion techniques to examine the localization of Gag in
transfected 293T cells and chronically infected MOLT T-
cells. Cell lysates prepared from virus-expressing cells
were fractionated on iodixanol gradients. The sedimenta-
tion of Gag was compared to that of markers for plasma
membrane, late endosomes, small vesicles, and soluble
proteins [46]. The results indicated that Gag was found in
fractions that corresponded to both the plasma mem-
brane and late endosomes. Genomic RNA was observed
primarily in late endosomal and soluble fractions. Similar
results were obtained in the MOLT T cells. These observa-
tions, which were confirmed by immunofluorescence and
electron microscopy, led the authors to conclude that
HIV-1 assembly in 293T and chronically infected T cells
takes place at both the plasma membrane and in MVBs.
Removal of the zinc fingers in the NC domain resulted in
a shift in Gag localization from endosomal to recycling
vesicle fractions, and a loss in the cosedimentation of Gag
and genomic RNA.
Assembly and release of retroviruses
Retroviral particle budding is promoted by small motifs in
Gag known as late domains (for review, see [47-49]).
These motifs stimulate virus release by interacting with
components of the cellular endosomal sorting machinery,
which regulate the delivery of cargo proteins into the MVB
pathway, and the biogenesis of the vesicles that bud into
MVBs. Three types of retroviral late domains have been
characterized: Pro-Thr/Ser-Ala-Pro [P(T/S)AP], Pro-Pro-x-
Pro (PPxY), and Tyr-Pro-xn-Leu (YPxnL). P(T/S)AP, the
dominant HIV-1 late domain found in Gag-p6, binds
Tsg101, a component of the ESCRT-I complex (endo-
somal sorting complex required for transport). PPxY late
domains interact with ubiquitin ligases in the Nedd4 fam-
ily, and YPxL motifs associate with Alix (also known as
AIP1). Interestingly, although P(T/S)AP is the major late
domain of HIV-1, p6 also bears a YPxnL-type motif that
has been shown to bind Alix.
In his keynote address, Wesley Sundquist discussed sev-
eral aspects of the cell biology and biochemistry of HIV-1
budding. He first described some of the cellular apparatus
that associates with Tsg101. In addition to the ESCRT-1
components Vps28 and Vps37, Tsg101 also binds Hrs,
Alix, the GGA proteins, and TOM1L1. Interestingly,
TOM1L1 also interacts with Nedd4-like E3 ubiquitin
ligases, raising the possibility that it might play a role in
the recruitment of PPxY-containing retroviruses into the
MVB pathway. Ubiquitination of cargo proteins is often
(but not always) required for their sorting into MVBs, and
there are several lines of evidence suggesting that ubiqui-
tination of Gag itself may play a positive role in virus
release. A number of components of the MVB machinery,
including Hrs, Tsg101, and the ESCRT-II component
EAP45, contain motifs that directly bind ubiquitin. HIV-1
Gag, for example, could interact with Tsg101 not only
through its P(T/S)AP motif in p6 but also through ubiqui-
tin moieties attached to several domains of Gag [50].
Purification and analysis of ESCRT-I complexes in Sun-
dquist's lab revealed a heretofore unrecognized fourth
component of ESCRT-I, referred to as EI4A (and variant
EI4B).
Finally, Sundquist described his lab's studies on Alix.
While it is now fairly clear that Alix is the major late-
domain-interacting protein for EIAV, as mentioned above
HIV-1 p6 also interacts with Alix. A role for Alix in HIV-1
release is most apparent when the Gag/Tsg101 interaction
has been abolished. Structural studies with the central,
Gag-binding domain of Alix revealed a V-shaped fold,
with the YPxnL binding site lying inside the base of the V.
The continuing discovery of additional components of
ESCRT and associated machinery adds to the complexity
of the endosomal sorting (and virus budding) machinery.
Sundquist pointed out that ~100 proteins are involved in
endocytosis and that a comparable number of proteins
may ultimately be implicated in MVB biogenesis. It will be
of great interest to define which of this multitude of cellu-
lar factors are required for the release of HIV-1 and other
retroviruses.
Previous studies from the lab of Jaisri Lingappa demon-
strated that HIV-1 assembly proceeds through the forma-
tion of a series of discrete intermediates of 10S, 80S, 150S,
and 500S, culminating in a 750S immature VLP [51]. The
subcellular localization of these assembly intermediates
was investigated by Lingappa and coworkers using mem-
brane flotation techniques. The 10S complex was found to
be cytosolic, the 80S/150S was in both cytosolic and
membrane-associated fractions, whereas the 500S and
750S complexes were predominantly found in mem-
brane. The assembly cofactor ABCE1 (formerly referred toPage 6 of 10
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brane fractions. Interestingly, in murine cells, which
according to some studies display a defect in HIV-1 parti-
cle production [53,54], assembly is arrested at the stage of
80S/150S complex formation.
Several labs, including Mark Marsh's, have previously
reported that in monocyte-derived macrophages HIV-1
assembly takes place primarily in a late endosome or MVB
compartment (for review, see [55]). Mark Marsh
expanded on this theme in his presentation and provided
a more refined view of the compartment in which assem-
bly occurs in this cell type. Using a combination of confo-
cal microscopy and immuno-EM, the colocalization of
Gag with a variety of tetraspannin markers previously
used to define the late endosome (e.g., CD9, CD53,
CD63, and CD81) was examined. Only partial overlap
was observed between Gag and CD63 (as previously
reported [56]), whereas colocalization of Gag with CD9
and CD81 was more extensive. Interestingly, organelles
positive for CD9, CD53 and CD81 displayed a complex
morphology with extensive internal membranes, suggest-
ing that this compartment may be distinct from that in
which CD63 is concentrated. A partial shift in CD63 local-
ization was observed in HIV-infected cells, raising the pos-
sibility that HIV may alter the CD9-, CD53-, and CD81-
containing compartment in infected macrophages.
An alternative perspective on the localization of HIV-1
assembly was provided by Nolwenn Jouvenet (P. Bieniasz
lab). Jouvenet presented a series of results that were used
to argue that HIV-1 assembly takes place on the plasma
membrane irrespective of the cell type in which Gag is
expressed. Chimeric Gag proteins that contain MVB-tar-
geting signals were severely defective in virus release,
whereas drugs that block late endosome mobility did not
affect virus particle production, even in macrophages.
These observations suggest that the localization of Gag to
the MVB may be part of a non-productive assembly path-
way. Thus, there currently exists a continuum of opinions
in the field regarding the site of HIV-1 assembly: some
have argued that MVB assembly predominates in all cell
types, others believe that the plasma membrane is the
major site of assembly regardless of cell type, and a third
group of investigators has reported that the site of assem-
bly is cell type-dependent, with HeLa and T-cells showing
predominantly plasma membrane assembly and primary
macrophages displaying a high level of MVB-associated
assembly. Real-time imaging of infected cells will be help-
ful in resolving this debate.
Paul Spearman presented his lab's findings on the locali-
zation and function of the HIV-1 accessory protein Vpu,
which possesses the ability to stimulate virus release from
most human cell types. Some of these results were pub-
lished recently [57]. Based on colocalization analyses with
cellular markers, Vpu was observed to be concentrated in
a recycling endosome compartment. Disruption of recy-
cling endosome function with dominant-negative ver-
sions of Rab11a or myosin Vb blocked the ability of Vpu
to promote virus release. Several reports have shown that
the Env glycoprotein from the ROD10 strain of HIV-2 pos-
sesses a Vpu-like ability to enhance HIV-1 release; this
activity of HIV-2 Env was also blocked by recycling endo-
some disruption. It has been postulated that Vpu acts by
counteracting a cellular protein that delays virus release,
thus favoring release over internalization of newly bud-
ded particles [57-59]. Given Vpu's localization in recy-
cling endosomes and its limited presence on the plasma
membrane, its ability to block the activity of a putatively
surface-associated factor might be indirect rather than
through a direct protein-protein interaction.
As mentioned above, HIV-1 budding is promoted by cel-
lular machinery that normally functions in the biogenesis
of vesicles that bud into late endosomes to form MVBs.
This machinery includes the three multiprotein com-
plexes ESCRT-I, II, and III. In human cells, the ESCRT-III
complex is composed of a set of CHMP (for charged MVB)
proteins [60]. Heinrich Gottlinger's lab has previously
reported that overexpression of CHMP3 and CHMP4a
proteins fused to red fluorescent protein (RFP) led to a
potent dominant-negative inhibition of HIV-1 release
[61]. At this meeting, Gottlinger reported the results of a
study that examined the ability of CHMP3 overexpression
to inhibit HIV-1 release. Because CHMP3 bears a highly
basic N-terminal domain and a highly acidic C-terminal
domain, Gottlinger postulated that an intramolecular
interaction might occur that would lead to autoinhibition
of CHMP3 function. According to this model, deletion of
either N- or C-terminal domain would relieve the autoin-
hibition and activate the protein. Gottlinger presented
evidence to support this model: N- and C-terminal
domains were observed to interact, and removal of the C-
terminal domain resulted in a protein capable of interfer-
ing with HIV-1 release. Activation of CHMP3 could also
be induced by overexpression of a reported CHMP3-bind-
ing partner, the ubiquitin isopeptidase AMSH [62].
In the final talk of the conference, Markus Thali reported
on the role of tetraspanins in virus release. Specifically, he
presented data indicating that HIV-1 localizes to regions
of the plasma membrane that are enriched in a set of tet-
raspanins that includes CD9, CD63, CD81, and CD82
[63]. The ESCRT-I components Tsg101 and Vps28 also
concentrate in these microdomains, suggesting that these
tetraspanin-enriched microdomains (TEMs) serve as plat-
forms for virus budding. Providing functional data in sup-
port of this hypothesis, Thali showed that an antibody
against CD9 inhibited HIV-1 release (consistent with anPage 7 of 10
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ferent anti-CD9 antibody [64]), apparently by clustering
TEMs. Interestingly, the budding of influenza virus was
not inhibited by the anti-CD9 antibody, suggesting that
orthomyxoviruses bud from plasma membrane microdo-
mains distinct from those used by HIV-1.
An overview of the HIV-1 replication cycle, with positive
and negative host factors indicated, is illustrated in Figure
1.
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